Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia

Diabetes Care

Volumn 38, Issue 6, 2015, Pages 1016-1029

  Choudhary, Pratik ^a   Rickels, Michael R ^b   Senior, Peter A ^c   Vantyghem, Marie Christine ^d   Maffi, Paola ^e   Kay, Thomas W ^f   Keymeulen, Bart ^g   Inagaki, Nobuya ^h   Saudek, Frantisek ⁱ   Lehmann, Roger ^j   Hering, Bernhard J ^k  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^h KYOTO UNIVERSITY   (Japan)

ⁱ INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^j UNIVERSITY OF ZURICH   (Switzerland)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; MYCOPHENOLATE MOFETIL; PIG INSULIN; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ALGORITHM; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL EFFECTIVENESS; CONTINUOUS GLUCOSE MONITORING; CONTINUOUS INFUSION; EDUCATION PROGRAM; EVIDENCE BASED PRACTICE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; MEDICAL TECHNOLOGY; MULTICENTER STUDY (TOPIC); PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PROBLEM SOLVING; PROBLEMATIC HYPOGLYCEMIA; SENSOR; AWARENESS; DIABETES MELLITUS, TYPE 1; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; METABOLISM; PATIENT EDUCATION; PROCEDURES;

ALGORITHMS; AWARENESS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; PANCREAS TRANSPLANTATION; PATIENT EDUCATION AS TOPIC;

EID: 84962438836     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0090     Document Type: Article

References (110)

1. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-3176.
2. McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. Diabetes 2010;59:2333- 2339.
3. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-1395.
4. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 2014;10:711-722.
5. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249.
6. Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004;20:479-486.
7. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-1147.
8. Gruden G, Barutta F, Chaturvedi N, et al. Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: The EURODIAB Prospective Complications Study. Diabetes Care 2012;35:1598-1604.
9. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98: 3411-3419.
10. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995;18:517-522.
11. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697-703.
12. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjectsundergoing islet transplantation. Diabetes 2004;53:955-962.
13. Cryer PE. Mechanisms of hypoglycemiaassociated autonomic failure in diabetes. N Engl J Med 2013;369:362-372.
14. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med 2008;25:501-504.
15. Choudhary P, Geddes J, Freeman JV, Emery CJ, Heller SR, Frier BM. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabet Med 2010;27:666- 672.
16. Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: The U.K. DAFNE experience. Diabetes Care 2012; 35:1638-1642.
17. Frier BM. Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res Clin Pract 2004; 65(Suppl. 1):S47-S52.
18. Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006;49:298-305.
19. Feltbower RG, Bodansky HJ, Patterson CC, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care 2008;31: 922-926.
20. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012;35: 1897-1901.
21. Sherr J, Tamborlane WV, Xing D, et al.; Diabetes Research in Children Network (DirecNet) Study Group. Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual b-cell function. Diabetes Care 2012;35:817-820.
22. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010;31:171-182.
23. Vantyghem MC, Raverdy V, Balavoine AS, et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (b-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (b-score greater than 3). J Clin Endocrinol Metab 2012;97:E2078-E2083.
24. Stuckey HL, Mullan-Jensen CB, Reach G, et al. Personal accounts of the negative and adaptive psychosocial experiences of people with diabetes in the second Diabetes Attitudes, Wishes and Needs (DAWN2) study. Diabetes Care 2014;37:2466-2474.
25. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-286.
26. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006;49:261-270.
27. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
28. Orchard TJ, Nathan DM, Zinman B, et al.; Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45-53.
29. Stadler M, Peric S, Strohner-Kaestenbauer H, et al. Mortality and incidence of renal replacement therapy in people with type 1 diabetes mellitusda three decade long prospective observational study in the Lainz T1DM cohort. J Clin Endocrinol Metab 2014;99:4523-4530.
30. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371:1972-1982.
31. Schoenaker DA, Simon D, Chaturvedi N, Fuller JH, Soedamah-Muthu SS; EURODIAB Prospective Complications Study Group. Glycemic control and all-cause mortality risk in type 1 diabetes patients: The EURODIAB prospective complications study. J Clin Endocrinol Metab 2014;99:800-807.
32. Cryer PE. Glycemic goals in diabetes: Tradeoff between glycemic control and iatrogenic hypoglycemia. Diabetes 2014;63:2188-2195.
33. Muhlhauser I, Bruckner I, Berger M, et al. Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest-Dusseldorf Study. Diabetologia 1987;30:681-690.
34. Samann A, Muhlhauser I, Bender R, Kloos Ch, Muller UA. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedomin peoplewith type 1 diabetes: a prospective implementation study. Diabetologia 2005;48: 1965-1970.
35. Samann A, Muhlhauser I, Bender R, Hunger- Dathe W, Kloos C, Muller UA. Flexible intensive insulin therapy in adults with type 1 diabetes and high risk for severe hypoglycemia and diabetic ketoacidosis. Diabetes Care 2006;29:2196-2199.
36. Cox D, Gonder-Frederick L, Polonsky W, Schlundt D, Julian D, Clarke W. A multicenter evaluation of blood glucose awareness training-II. Diabetes Care 1995;18:523-528.
37. Broers S, van Vliet KP, le Cessie S, Spinhoven P, van der Ven NC, Radder JK. Blood glucose awareness training in Dutch type 1 diabetes patients: one-year follow-up. Neth J Med 2005;63: 164-169.
38. Schachinger H, Hegar K, Hermanns N, et al. Randomized controlled clinical trial of Blood Glucose Awareness Training (BGAT III) in Switzerland and Germany. J Behav Med 2005;28: 587-594.
39. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993;42:1683- 1689.
40. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulindependent diabetes. Lancet 1994;344:283-287.
41. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994;43:1426-1434.
42. Fanelli C, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM (published correction appears in Diabetolgia 1995;38:254). Diabetologia 1994;37: 1265-1276.
43. Cox DJ, Kovatchev B, Koev D, et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. Int J Behav Med 2004;11:212-218.
44. Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 2010;33:e36.
45. Rankin D, Elliott J, Heller S, et al. Experiences of hypoglycaemia unawareness amongst people with Type 1 diabetes: a qualitative investigation. Chronic Illn 2013;10:180-191.
46. Rogers HA, de Zoysa N, Amiel SA. Patient experience of hypoglycaemia unawareness in type 1 diabetes: are patients appropriately concerned? Diabet Med 2012;29:321-327.
47. de Zoysa N, Rogers H, Stadler M, et al. A psychoeducational program to restore hypoglycemia awareness: The DAFNE-HART pilot study. Diabetes Care 2014;37:863-866.
48. Little SA, Leelarathna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in longstanding type 1 diabetes: a multicenter 2 3 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose selfmonitoring (HypoCOMPaSS). Diabetes Care 2014;37:2114-2122.
49. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 2011;13(Suppl. 1):S53-S64.
50. Holleman F, Gale EA. Nice insulins, pity about the evidence. Diabetologia 2007;50: 1783-1790.
51. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009;180:385-397.
52. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614-1620.
53. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009;11:372-378.
54. Tricco AC, Antony J, Khan PA, et al. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failingtwo oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open 2014;4:e005752.
55. Heller S, Buse J, Fisher M, et al.; BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-1497.
56. Pedersen-Bjergaard U, Kristensen PL, Beck- Nielsen H, et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol 2014;2:553-561.
57. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: metaanalysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-774.
58. Giḿenez M, Lara M, Conget I. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study. Diabetes Technol Ther 2010;12:517-521.
59. Chetty VT, Almulla A, Odueyungbo A, Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HbA1c) levels in type I diabetic patients: a systematic review. Diabetes Res Clin Pract 2008;81:79-87.
60. Szypowska A, Ramotowska A, Dzygalo K, Golicki D. Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials. Eur J Endocrinol 2012;166:567-574.
61. Leelarathna L, Little SA, Walkinshaw E, et al. Restoration of self-awareness of hypoglycemia in adults with long-standing type 1 diabetes: hyperinsulinemic-hypoglycemic clamp substudy results from the HypoCOMPaSS trial. Diabetes Care 2013;36:4063-4070.
62. Bergenstal RM, Tamborlane WV, Ahmann A, et al.; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311- 320.
63. Buckingham B, Block J, Burdick J, et al.; Diabetes Research in Children Network. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther 2005;7:440-447.
64. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224-232.
65. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310: 1240-1247.
66. Choudhary P, Ramasamy S, Green L, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care 2013;36:4160-4162.
67. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313- 325.
68. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342:d1855.
69. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dualhormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015;3:17-26.
70. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol 2013;9:555-562.
71. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012;35: 1436-1445.
72. Niclauss N, Morel P, Berney T. Has the gap between pancreas and islet transplantation closed? Transplantation 2014;98:593-599.
73. Bassi R, Fiorina P. Impact of islet transplantation on diabetes complications and quality of life. Curr Diab Rep 2011;11:355-363.
74. Thompson DM, Meloche M, Ao Z, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 2011;91:373-378.
75. Robertson RP. Islet transplantation for type 1 diabetes, 2015: what have we learned from alloislet and autoislet successes? Diabetes Care 2015;38:1030-1035.
76. Kendall DM, Rooney DP, Smets YF, Salazar Bolding L, Robertson RP. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. Diabetes 1997;46: 249-257.
77. Rickels MR, Fuller C, Dalton-Bakes C, et al. Restoration of glucose counterregulation by islet transplantation in long-standing type 1 diabetes. Diabetes 2015;64:1713-1718.
78. Rickels MR, Mueller R, Teff KL, Naji A. b-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab 2010;95:1238-1246.
79. Rickels MR, Liu C, Shlansky-Goldberg RD, et al. Improvement in b-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes 2013;62:2890- 2897.
80. Paty BW, Lanz K, Kendall DM, Sutherland DE, Robertson RP. Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation 2001;72: 1103-1107.
81. Barrou Z, Seaquist ER, Robertson RP. Pancreas transplantation in diabetic humans normalizes hepatic glucose production during hypoglycemia. Diabetes 1994;43:661-666.
82. Matsumoto I, Sawada T, Nakano M, et al. Improvement in islet yield from obese donors for human islet transplants. Transplantation 2004;78:880-885.
83. Gruessner AC, Sutherland DE, Gruessner RW. Long-term outcome after pancreas transplantation. Curr Opin Organ Transplant 2012; 17:100-105.
84. Sollinger HW, Odorico JS, Becker YT, D'Alessandro AM, Pirsch JD. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg 2009;250:618-630.
85. Lehmann R, Graziano J, Brockmann J, et al. Glycemic control in simultaneous islet-kidney versus pancreas-kidney transplantation in type 1 diabetes: a prospective 13-year follow-up. Diabetes Care 2015;38:752-759.
86. Gruessner RW, Dunn DL, Gruessner AC, Matas AJ, Najarian JS, Sutherland DE. Recipient risk factors have an impact on technical failure and patient and graft survival rates in bladderdrained pancreas transplants. Transplantation 1994;57:1598-1606.
87. Kandaswamy R, Sutherland DE. Pancreas versus islet transplantation in diabetes mellitus: how to allocate deceased donor pancreata? Transplant Proc 2006;38:365-367.
88. Senior PA, Bellin MD, Alejandro R, et al. Consistency of quantitative scores of hypoglycemia severity and glycemic lability and comparision with continuous glucose monitoring system measures in long-standing type 1 diabetes. Diabetes Technol Ther 2015;17:235-242.
89. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 2012;12:1576-1583.
90. Qi M, Kinzer K, Danielson KK, et al. Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: The UIC experience. Acta Diabetol 2014;51:833-843.
91. Clinical Islet Transplantation Consortium. Available from http://www.isletstudy.org. Accessed 2 February 2015.
92. O'Connell PJ, Holmes-Walker DJ, Goodman D, et al.; Australian Islet Transplant Consortium. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. Am J Transplant 2013;13:1850-1858.
93. Brooks AM, Walker N, Aldibbiat A, et al. Attainment of metabolic goals in the integrated UK islet transplant programwith locally isolated and transported preparations. Am J Transplant 2013;13:3236-3243.
94. Ang M, Meyer C, Brendel MD, Bretzel RG, Linn T. Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes. Diabetologia 2014;57:623-632.
95. Paty BW, Senior PA, Lakey JR, Shapiro AM, Ryan EA. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin- requiring type 1 diabetes subjects. Diabetes Technol Ther 2006;8:165-173.
96. Gorn L, Faradji RN, Messinger S, et al. Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system. J Diabetes Sci Tech 2008;2:221-228.
97. Brooks AM, OramR, Home P, Steen N, Shaw JA. Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation. Diabetes Care 2015;38:105-112.
98. Cryer PE. Hypoglycemia begets hypoglycemia in IDDM. Diabetes 1993;42:1691-1693.
99. Gerber PA, Pavlicek V, Demartines N, et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia 2008; 51:110-119.
100. Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported nonsevere hypoglycaemic events in Europe. Diabet Med 2014;31:92-101.
101. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998;21:1870-1875.
102. Kovatchev BP, Otto E, Cox D, Gonder- Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006;29:2433-2438.
103. Bode BW, Buse JB, FisherM, et al.; BEGIN- Basal-Bolus Type 1 Trial Investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN(-) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013;30:1293-1297.
104. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011;343:d3805.
105. Wiseman AC. Pancreas transplant options for patients with type 1 diabetes mellitus and chronic kidney disease: simultaneous pancreas kidney or pancreas after kidney? Curr Opin Organ Transplant 2012;17:80-86.
106. Maffi P, Bertuzzi F, De Taddeo F, et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 2007;30:1150-1155.
107. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
108. Klein AS, Messersmith EE, Ratner LE, Kochik R, Baliga PK, Ojo AO. Organ donation and utilization in the United States, 1999- 2008. Am J Transplant 2010;10:973-986.
109. Matesanz R, Doḿinguez-Gil B, Coll E, de la Rosa G, Marazuela R. Spanish experience as a leading country: what kind of measures were taken? Transpl Int 2011;24:333-343.
110. Byrne ML, Hopkins D, Littlejohn W, et al. Outcomes for adults with type 1 diabetes referred with severe hypoglycaemia and/or referred for islet transplantation to a specialist hypoglycaemia service. Horm Metab Res 2015; 47:9-15.